American Journal of Tropical Medicine and Hygiene · 2005 · 50 citations · 20 references
PharmacyDermatologyPharmacotherapyDosage Form DesignImmunopharmacologyImmunotherapyDose EscalationDose OptimizationRecurrenceTaperingThalidomide AnalogsTreatment Tapering
In a randomized, double-blind, double-dummy controlled study, 22 men with erythema nodosum leprosum (ENL) received six capsules containing either 100 mg (group A, n = 12) or 300 mg (group B, n = 10) of thalidomide daily for one week. A six-week, four capsules per day taper followed, in which group A received 50 mg/day of thalidomide in weeks 2 and 3, then dummy capsules in weeks 4 through 7, while group B had gradual decrements every two weeks. Both regimens caused comparable improvement in 19 patients at day 7 (group A [12 of 12] versus group B [7 of 10]; P = 0.08), but slower tapering in group B showed less re-emergence of ENL through week 7 (P = 0.02, versus group A). Most patients developed new lesions soon after stopping treatment. Slower tapering from a higher initial thalidomide dose may improve clinical ENL responses, but high recurrence rates after discontinuation indicates further assessment is needed to identify better tapering regimens.
20
Patrick Haslett, Laura G. Corral, Matthew L. Albert et al. · The Journal of Experimental Medicine · 1998 · 573 citations · Full text
Thalidomide in the treatment of lepra reactions
J Sheskin · Clinical Pharmacology & Therapeutics · 1965 · 533 citations
Gilbert W. Mellin, Michael Katzenstein · New England Journal of Medicine · 1962 · 226 citations